Lidocan III (Lidocaine) Patent Expiration, LOE Window & CMS Spending

Lidocan III (Lidocaine) by Puretek Corpora: Off-Patent Genericized (AB Competition), 8 AB generics, $2.0M 2024 CMS Part D & Medicaid spend, and $828 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPuretek Corpora
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$2.0M
2024 Medicare Part D Spend$517K
2024 Medicaid Spend$1.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($828 intro WAC)